Roivant Sciences LTD Form 4 insider transactions

Matthew Gline, CEO of Roivant Sciences, reports a transaction involving the disposal of common shares to cover tax obligations related to vested RSUs.

Richard Pulik, CFO of Roivant Sciences, disposed of 2,340 common shares to cover tax obligations related to vested RSUs.

QVT Financial LP reports the sale of Roivant Sciences Ltd. shares, decreasing its beneficial ownership.

Director Keith Manchester of Roivant Sciences Ltd. sold a portion of his common shares in two transactions on September 24 and 25, 2024.

Director Daniel Gold reports the sale of Roivant Sciences shares through direct and indirect holdings across multiple transactions.

Roivant Sciences CEO Matthew Gline exercised stock options and sold shares to cover tax obligations and option exercise costs, while affirming no plans for further near-term sales.

Richard Pulik, CFO of Roivant Sciences, disposed of 2,129 common shares on September 20, 2024, to cover tax withholding obligations related to the vesting of RSUs.

Rakhi Kumar, Chief Accounting Officer of Roivant Sciences, reports the acquisition and disposal of common shares, including transactions related to stock options and tax obligations.

Eric Venker, President & COO of Roivant Sciences, disposed of 10,945 common shares to cover tax withholding obligations related to vested RSUs.

Director Ilan Oren disposed of 3,487 common shares of Roivant Sciences Ltd. to cover tax withholding obligations related to vested RSUs.

Director James C Momtazee sold 3,056 common shares of Roivant Sciences Ltd. to cover tax obligations related to the vesting and settlement of RSUs.

Director Daniel Allen Gold sold 2,599 common shares of Roivant Sciences Ltd. to cover tax obligations related to vested RSUs.

Director Melissa Epperly sold 4,245 common shares of Roivant Sciences to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Director Meghan Fitzgerald sold 894 common shares of Roivant Sciences Ltd. on September 12, 2024, to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Keith Manchester, a director of Roivant Sciences Ltd., was granted stock options and restricted stock units (RSUs) as part of the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.

Director Daniel Allen Gold received stock options and restricted stock units from Roivant Sciences Ltd. on September 10, 2024, according to a Form 4 filing.

Director Melissa Epperly received stock options and restricted stock units from Roivant Sciences as part of the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.

Director Ilan Oren received an annual award of restricted stock units and stock options from Roivant Sciences Ltd.

Director Meghan Fitzgerald received stock options and restricted stock units from Roivant Sciences on September 10, 2024, according to a Form 4 filing.

Director James C Momtazee received stock options and restricted stock units from Roivant Sciences Ltd. on September 10, 2024.

Richard Pulik, CFO of Roivant Sciences, disposed of 2,341 common shares on August 28, 2024, to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Rakhi Kumar, Chief Accounting Officer of Roivant Sciences, disposed of 958 common shares to cover tax obligations related to vested RSUs.

Eric Venker, President & COO of Roivant Sciences, disposed of 10,947 common shares to cover tax obligations related to vested RSUs.

Matthew Gline, CEO of Roivant Sciences, disposed of 10,947 common shares to cover tax obligations related to vested RSUs.

Roivant Sciences CEO Matthew Gline received awards of restricted stock units (RSUs) and performance-based stock units (PSUs) on July 26, 2024.

Mayukh Sukhatme, President & Chief Investment Officer of Roivant Sciences, reports the acquisition of substantial restricted stock units (RSUs) and performance-based stock units (PSUs).

Roivant Sciences' President and COO, Eric Venker, reports the acquisition of restricted stock units and stock options.

Richard Pulik, CFO of Roivant Sciences, disposed of 2,341 common shares on July 28, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Eric Venker, President & COO of Roivant Sciences Ltd., reports a transaction involving common shares to cover tax obligations related to vested RSUs.

Roivant Sciences CEO Matthew Gline disposed of 10,945 common shares to cover tax obligations related to vested RSUs.